25 Seats. Five Pillars.
Zero audience. The room is strictly limited to 25 principal decision-makers across capital, biopharma, law, policy, and digital asset protocols.
40
Total Capacity
100%
Principal Level
5
Market Vectors
1
Shared Outcome
Seat Composition
The 5 Stakeholder Vectors
OCTOBER 5, 2026 • MUMBAI
Pillar 01
Family Offices & Allocators
UHNI family principals and sovereign wealth directors seeking non-correlated, asset-backed scientific yields.
Primary Role
Underwriting liquidity and primary SAR asset acquisition.
Pillar 02
Family Offices & Allocators
Biopharma founders and institute heads holding late-stage patents, clinical data, and IP assets.
Primary Role
Supplying scientific assets into trustee-held SPVs.
Pillar 03
Market Intermediaries
Investment banking leaders, legal partners, and trustee custodians governing SPV isolation.
Primary Role
Structuring bankruptcy-remote trustee & debt frameworks.
Pillar 04
Policy & Regulatory Voices
Regulatory advisors aligned with SEBI, GIFT City frameworks, and institutional guidelines.
Primary Role
Ensuring REIT/InvIT regulatory precedent alignment.
Pillar 05
Global Nodes & Digital Asset Protocols
Real-World Asset (RWA) protocol architects connecting the Mumbai table to Singapore liquidity pools.
Primary Role
Digital settlement rails and cross-border secondary market liquidity.
16
of 25 seats are capital, pharma or financial markets
The Invitation Math
We mustn't let the desire for an impressive international guest list dilute the commercial density of the room.
One question goes around the table: "What would have to be true for your institution to allocate capital?
"Every registration is personally reviewed, and invitations are issued one at a time as the room is composed.
BY INVITATION ONLY
Request a Seat at The Scientific Capital Table
Participation is strictly limited to 40 primary decision-makers across Sovereign Funds, Family Offices, Biopharma CEOs, Market Intermediaries, and Policy Leaders.
